Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;11(3):226-31.
doi: 10.1007/s12519-014-0517-6. Epub 2014 Nov 20.

Growth patterns in children with mucopolysaccharidosis I and II

Affiliations

Growth patterns in children with mucopolysaccharidosis I and II

Agnieszka Różdżyńska-Świątkowska et al. World J Pediatr. 2015 Aug.

Abstract

Background: Mucopolysaccharidosis (MPS) diseases lead to a profound disruption in normal mechanisms of growth and development. This study was undertaken to determine the general growth of children with MPS I and II.

Methods: The anthropometric data of patients with MPS I and II (n=76) were retrospectively analyzed. The growth patterns of these patients were analyzed and then plotted onto Polish reference charts. Longitudinal analyses were performed to estimate age-related changes.

Results: At the time of birth, the body length was greater than reference charts for all MPS groups (Hurler syndrome, P=0.006; attenuated MPS II, P=0.011; severe MPS II, P<0.001). The mean z-score values for every MPS group showed that until the 30th month of life, the growth patterns for all patients were similar. Afterwards, these growth patterns start to differ for individual groups. The body height below the 3rd percentile was achieved around the 30th month for boys with Hurler syndrome, between the 4th and 5th year for patients with severe MPS II and between the 7th and 8th year for patients with attenuated MPS II.

Conclusions: The growth pattern differs between patients with MPS I and II. It reflects the clinical severity of MPS and may assist in the evaluation of clinical efficacy of available therapies.

PubMed Disclaimer

References

    1. Pediatrics. 2009 Jan;123(1):229-40 - PubMed
    1. Eur J Pediatr. 2008 Mar;167(3):267-77 - PubMed
    1. Am J Med Genet A. 2008 May 15;146A(10):1286-95 - PubMed
    1. Arch Dis Child. 1982 Nov;57(11):828-36 - PubMed
    1. Lab Invest. 2001 Sep;81(9):1319-28 - PubMed

LinkOut - more resources